Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer

Critical Reviews in Clinical Laboratory Sciences

Volumn 48, Issue 4, 2011, Pages 155-170

  Allin, Kristine H ^a   Nordestgaard, Børge G ^a  

^a University of Copenhagen ^*  (Denmark)

Author keywords

Acute phase protein; Biomarker; Causality; Chronic inflammation; Mendelian randomization

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CHRONIC INFLAMMATION; COLORECTAL CANCER; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LUNG CANCER; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; OCCULT CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SOLID TUMOR;

C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; NEOPLASMS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80155135586     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2011.599831     Document Type: Review

References (127)

1. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357:539-545. (Pubitemid 32173595)
2. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancerrelated inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009;30:1073-1081.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867. (Pubitemid 36019639)
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444.
6. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78. (Pubitemid 38082155)
7. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4:641-648. (Pubitemid 39025049)
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
9. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004;279:48487-48490. (Pubitemid 39625721)
10. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: A critical review. J Intern Med 2008;264:295-314.
11. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454. (Pubitemid 29084777)
12. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: New insights from an old molecule. Qjm 2003;96:793-807. (Pubitemid 37369294)
13. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-1812. (Pubitemid 38057722)
14. Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61:824-833.
15. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-2224.
16. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010;28:2719-2726.
17. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291: 585-590. (Pubitemid 38500312)
18. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483-2487.
19. Heikkilä K, Silander K, Salomaa V, Jousilahti P, Koskinen S, Pukkala E et al. C-reactive protein-associated genetic variants and cancer risk: Findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer 2011;47:404-412.
20. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-2418. (Pubitemid 41437845)
21. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S; Japan Public Health Center-Based Prospective Study Group. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006;15:690-695.
22. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study. J Clin Oncol 2006;24:5216-5222. (Pubitemid 46631365)
23. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: A prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-384. (Pubitemid 43348407)
24. Nordestgaard BG. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Curr Opin Lipidol 2009;20:393-401.
25. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF et al.; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010;31:2844-2853.
26. Nordestgaard BG, Tybjærg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: Concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol 2011;22:113-122.
27. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-163.
28. Burtis CA, Ashwood ER, and Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4. 2006. Elsevier Saunders.
29. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561-571.
30. Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E. Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 1977;74:739-743. (Pubitemid 8038801)
31. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7:169-177. (Pubitemid 29159702)
32. Kinoshita CM, Ying SC, Hugli TE, Siegel JN, Potempa LA, Jiang H et al. Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry 1989;28:9840-9848. (Pubitemid 20022333)
33. Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J 2007;21:284-294.
34. Whitehead AS, Bruns GA, Markham AF, Colten HR, Woods DE. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science 1983;221:69-71. (Pubitemid 13061692)
35. Lei KJ, Liu T, Zon G, Soravia E, Liu TY, Goldman ND. Genomic DNA sequence for human C-reactive protein. J Biol Chem 1985;260:13377-13383. (Pubitemid 16209818)
36. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: A comparison of monozygotic and dizygotic twins. Clin Chem 2004;50:130-134. (Pubitemid 38125709)
37. Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001;38:189-197. (Pubitemid 32786776)
38. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A et al. Human CRP gene polymorphism influences CRP levels: Implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003;23:2063-2069. (Pubitemid 37433201)
39. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77. (Pubitemid 40848037)
40. Kovacs A, Green F, Hansson LO, Lundman P, Samnegård A, Boquist S et al. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 2005;178:193-198. (Pubitemid 39600833)
41. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 2005;69: 623-638. (Pubitemid 41556317)
42. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004;13: 137-147. (Pubitemid 38072141)
43. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002;3:14-19. (Pubitemid 38961100)
44. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005;83: 440-447. (Pubitemid 40922166)
45. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002;162:217-219. (Pubitemid 34327361)
46. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. Jama 2009;302:37-48.
47. Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chasman DI et al. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 α are associated with C-reactive protein. Am J Hum Genet 2008;82:1193-1201.
48. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE et al. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: The Women's Genome Health Study. Am J Hum Genet 2008;82:1185-1192.
49. Li SP, Goldman ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 1996;35:9060-9068. (Pubitemid 26249852)
50. Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G. Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. Embo J 1990;9:4467-4475. (Pubitemid 120026004)
51. Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjærg-Hansen A et al. C-reactive protein levels and body mass index: Elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes (Lond) 2011;35: 300-308.
52. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon β 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-7255.
53. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest 1994;94:1390-1396. (Pubitemid 24309855)
54. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-1357. (Pubitemid 23127332)
55. Pepys MB, Dash AC, Fletcher TC, Richardson N, Munn EA, Feinstein A. Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature 1978;273:168-170. (Pubitemid 8322623)
56. Pepys MB. Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology 1979;37:637-641. (Pubitemid 9227124)
57. Volanakis JE, Wirtz KW. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature 1979;281:155-157. (Pubitemid 9251179)
58. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974;112:2135-2147.
59. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Part 2. Clin Chem 2001;47:418-425. (Pubitemid 32222454)
60. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511. (Pubitemid 36158056)
61. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001;47:426-430. (Pubitemid 32222455)
62. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: Implications for cardiovascular disease risk assessment. Clin Chem 2003;49: 1258-1271. (Pubitemid 36900610)
63. Young I, Rifai N. High-sensitivity C-reactive protein and cardiovascular disease. Clin Chem 2009;55:201-202.
64. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: Age-related values in the adult general population. Clin Chem 2000;46:934-938. (Pubitemid 30461263)
65. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005;352:1611-1613. (Pubitemid 40517111)
66. Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2007;99:890-894. (Pubitemid 47073511)
67. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-716. (Pubitemid 29383640)
68. Imhof A, Fröhlich M, Loewel H, Helbecque N, Woodward M, Amouyel P et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003;49: 669-672. (Pubitemid 36379539)
69. Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: Implication for clinical interpretation. Clin Chem 2003;49: 666-669. (Pubitemid 36379538)
70. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 2004;93:1238-1242. (Pubitemid 38595677)
71. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-450. (Pubitemid 32222458)
72. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Longterm effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235. (Pubitemid 29340127)
73. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242. (Pubitemid 29056365)
74. Nordestgaard BG, Adourian AS, Freiberg JJ, Guo Y, Muntendam P, Falk E. Risk factors for near-term myocardial infarction in apparently healthy men and women. Clin Chem 2010;56: 559-567.
75. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836-843. (Pubitemid 30165206)
76. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565. (Pubitemid 35315836)
77. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-1908.
78. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-428. (Pubitemid 28090212)
79. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama 2001;285:2481-2485. (Pubitemid 32433842)
80. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
81. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-1861.
82. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-850. (Pubitemid 28496456)
83. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997;82:4196-4200. (Pubitemid 27525539)
84. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2003;23:650-655. (Pubitemid 36438079)
85. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-978. (Pubitemid 29177345)
86. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD et al.; West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-1600. (Pubitemid 34826630)
87. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 2001;286:327-334. (Pubitemid 32656163)
88. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol 2010;56:789-795.
89. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010;30:1672-1678.
90. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. Jama 2003;290:2945-2951. (Pubitemid 37505526)
91. Dahl M, Vestbo J, Zacho J, Lange P, Tybjærg-Hansen A, Nordestgaard BG. C reactive protein and chronic obstructive pulmonary disease: A Mendelian randomisation approach. Thorax 2011;66:197-204.
92. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and all-cause mortality-the Copenhagen City Heart Study. Eur Heart J 2010;31:1624-1632.
93. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005;142:425-432.
94. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: A systematic review of prospective studies. Int J Cancer 2008;123: 1133-1140.
95. Platz EA, De Marzo AM, Erlinger TP, Rifai N, Visvanathan K, Hoffman SC et al. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate 2004;59:393-400. (Pubitemid 38661806)
96. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-2114.e5.
97. Cole SW. Chronic inflammation and breast cancer recurrence. J Clin Oncol 2009;27:3418-3419.
98. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-269. (Pubitemid 46486616)
99. Ostrand-Rosenberg S. Immune surveillance: A balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008;18:11-18. (Pubitemid 351694442)
100. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 2010;10:2-3.
101. Davey Smith G, Ebrahim S. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32:1-22. (Pubitemid 36503465)
102. Smith GD, Ebrahim S. Mendelian randomization: Prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42. (Pubitemid 38528650)
103. Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA. Limits to causal inference based on Mendelian randomization: A comparison with randomized controlled trials. Am J Epidemiol 2006;163:397-403.
104. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. C-reactive protein and the risk of cancer: A mendelian randomization study. J Natl Cancer Inst 2010;102:202-206.
105. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001;358:1356-1360. (Pubitemid 33016504)
106. Smith GD. Mendelian randomization for strengthening causal inference in observational studies: Application to gene x environment interactions. Perspect Psycholl Sci 2010;5:527-545.
107. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2011;
108. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: Quantification of bias. J Natl Cancer Inst 2000;92:1151-1158.
109. Schmid M, Schneitter A, Hinterberger S, Seeber J, Reinthaller A, Hefler L. Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. Obstet Gynecol 2007;110:1231-1236. (Pubitemid 351326063)
110. Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A et al. C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 2007;107:114-117. (Pubitemid 47464551)
111. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K et al. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 2008;98: 540-544.
112. Nielsen HJ, Christensen IJ, Sørensen S, Moesgaard F, Brünner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000;7:617-623.
113. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21-23. (Pubitemid 40188430)
114. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005;103:1856-1864. (Pubitemid 40563258)
115. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant hostand tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003;238:197-202. (Pubitemid 38174493)
116. Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: The TNM-C score. J Urol 2009;181:1004-12; discussion 1012.
117. Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008;101:978-981. (Pubitemid 351422558)
118. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG et al.; ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Results from the ASCENT trial. Cancer 2008;112:2377-2383.
119. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pretreatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: A cohort study. Breast Cancer Res 2011;13:R55.
120. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009;27:3437-3444.
121. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008;14: 710-714. (Pubitemid 351231151)
122. O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 2010;5:988-992.
123. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem 2008;54:335-342. (Pubitemid 351302620)
124. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009;249:788-793.
125. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5: 845-856. (Pubitemid 41746029)
126. Sawyers CL. The cancer biomarker problem. Nature 2008;452: 548-552. (Pubitemid 351483368)
127. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011;8:142-150.